Hot Features
Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
SANTA MONICA, Calif., April 28 /PRNewswire-FirstCall/ -- Aida Pharmaceuticals, Inc. (OTC:AIDA) (BULLETIN BOARD: AIDA) today announced that the Company is compiling data for its Phase 2 testing...
SANTA MONICA, Calif., April 24 /PRNewswire-FirstCall/ -- Aida Pharmaceuticals, Inc. (OTC:AIDA) (BULLETIN BOARD: AIDA) today announced that it has completed the acquisition of a controlling...
SANTA MONICA, Calif., April 22 /PRNewswire-FirstCall/ -- Aida Pharmaceuticals, Inc. (OTC:AIDA) (BULLETIN BOARD: AIDA) today announced the availability of an investor-focused corporate synopsis...
SANTA MONICA, Calif., April 18 /PRNewswire-FirstCall/ -- Aida Pharmaceuticals, Inc. (OTC:AIDA) (BULLETIN BOARD: AIDA) (hereinafter referred to as "Aida") today announced that it is developing a...
SANTA MONICA, Calif., April 9, 2008 /PRNewswire-FirstCall/ -- Aida Pharmaceuticals, Inc. (OTC:AIDA) (BULLETIN BOARD: AIDA) today announced that its recently-acquired research institute in the...
Report Shows 88% Increase in Net Income and Doubling of Net Margins SANTA MONICA, Calif., April 1, 2008 /PRNewswire-FirstCall/ -- Aida Pharmaceuticals, Inc. (OTC:AIDA) (BULLETIN BOARD: AIDA...
Acquisition Expected to Add New Drug Products to Aida Pharmaceuticals, Inc.'s Product Line SANTA MONICA, Calif., March 27 /PRNewswire-FirstCall/ -- Aida Pharmaceuticals, Inc. (OTC:AIDA...
SANTA MONICA, Calif., Jan. 7 /PRNewswire-FirstCall/ -- Aida Pharmaceuticals, Inc. (OTC:AIDA) (BULLETIN BOARD: AIDA) today announced that it has received an award from the Science and Technology...
SANTA MONICA, Calif., Dec. 4 /PRNewswire-FirstCall/ -- Aida Pharmaceuticals (OTC:AIDA) (BULLETIN BOARD: AIDA) today announced that the company's upcoming Rh-Apo2L cancer drug has been named as...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 12 | -0.0001 | -33.3333333333 | 0.0003 | 0.0003 | 0.0002 | 5285 | 0.00026308 | CS |
| 26 | 0 | 0 | 0.0002 | 0.0003 | 0.0002 | 4408 | 0.00023241 | CS |
| 52 | 0 | 0 | 0.0002 | 0.0003 | 0.0002 | 3413 | 0.00022442 | CS |
| 156 | -0.0098 | -98 | 0.01 | 0.01 | 0.0001 | 8123 | 0.00061294 | CS |
| 260 | -0.0168 | -98.8235294118 | 0.017 | 0.18 | 0.0001 | 23803 | 0.05191082 | CS |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
